mRNA Expression and Clinical Significance of ERCC1, BRCA1, RRM1, TYMS and TUBB3 in Postoperative Patients with Non-Small Cell Lung Cancer

Background: To explore mRNA expression and clinical significance of ERCC1, BRCA1, RRM1, TYMS andTUBB3 genes in tumor tissue of postoperative patients with non-small cell lung cancer (NSCLC). Materialsand
Methods: Sixty NSCLC patients undergoing radical operation in our hospital from Nov., 2011 to Jun.,2012 were selected. Plasmid standards of ERCC1, BRCA1, RRM1, TYMS and TUBB3 were established andstandard curves were prepared by SYBR fluorescent real-time quantitative PCR analysis. Samples fromtumor centers were taken to detect mRNA expression of ERCC1, BRCA1, RRM1, TYMS and TUBB3 genesin cancerous tissue during operation. The total mRNA expression quantities were compared according todifferent clinical characteristics.
Results: The total expression quantities of 5 genotypes from high to low wereERCC1>RRM1>TUBB3>TYMS>BRCA1 in turn. By pairwise comparisons, other differences showed statisticalsignificance (p<0.05 or p<0.01) except for TYMS and TUBB3 (p>0.05); the low expression rates from high to lowwere ERCC1>TYMS>TUBB3>TUBB3>RRM1>BRCA1 in turn. The expression quantities of BRCA1, RRM1 andTYMS in males, smokers and patients without adenocarcinoma were all significantly higher than that in females,non-smokers and patients with adenocarcinoma, and significant differences were present (p<0.05 or p<0.01).In terms of pathological staging, the expression quantities of BRCA1, RRM1 and TYMS in phases Ⅱa~Ⅱb andⅢa~Ⅲb had a tendency to be greater than in phases Ⅰ and Ⅳ.
Conclusions: Resistance to chemotherapy andsensitivity to targeted therapy differ among patients with NSCLC. Differences in gene expression in differentindividuals were also revealed. Only according to personalized detection results can individualized therapeuticregimens be worked out, which is a new direction for oncotherapy.